Discovery of amplified muscarinic signaling in chemoresistant prostate cancer
Combining antimuscarinic compounds with chemotherapy sensitizes chemonaive and resensitizes chemoresistant prostate cancer cells to chemotherapy and leads to widespread cancer cell death
Expansion into non-small cell lung cancer
Launching Chemosense
Founding of Chemosense Therapeutics by Dr. Bland and Dr. Wu
IP protection through submission of a non-provisional patent
Establishing Funding
Applying for SBIR/STTR Grants from the National Institute of Health
Applying for funding from the Health Sciences & Services Authority of Spokane County (HSSA)
Preclinical Studies
Optimize the dosing strategy for each drug in our novel combination therapy
Validate efficacy in a preclinical model
Partnerships
Establish partnerships with pharmaceutical and biotech companies to expand their platforms
Expansion Into More Cancer Types
Many cancers develop resistant to chemotherapeutics
Multiple other cancer types show increased muscarinic signaling
Begin preclinical testing of our therapy in these cancer types
